Clinical Trials Logo
  1. Home
  2. Ocular Melanoma
  3. NCT00346372
  4. Details
NCT00346372 Clinical Trial

Optical Coherence Tomography of Retinal Abnormalities Associated With Choroidal Nevus, Choroidal Melanoma and Choroidal Melanoma Treated With Iodine-125 Brachytherapy

Ocular Melanoma Clinical Trial

Clinical Trial Details — Status: Terminated

Administrative data
NCT number NCT00346372
Other study ID # UCLA IRB#03-11-052
Secondary ID
Status Terminated
Phase
First received
Last updated
Start date March 2004
Est. completion date November 27, 2017

Study information
Verified date January 2018
Source Jonsson Comprehensive Cancer Center
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

During regularly scheduled appointments, Optical Coherence Tomography (OCT) is performed on consented subjects. The OCT is a new type of camera that takes very detailed pictures inside of the eye and deeper into eye tissues. Optical Coherence Tomography imaging of intraocular tumors may lead to improved diagnosis and monitoring of tumors within the eye.

Recruitment information / eligibility
Status Terminated
Enrollment 5
Est. completion date November 27, 2017
Est. primary completion date November 27, 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Adults (18 years or older) with:

- choroidal nevus greater than or equal to 3.0 mm in longest basal diameter, or greater than or equal to 1.25 mm in apical height or:

- choroidal melanoma located in the posterior pole (4mm or less from the center of fovea or the border of the optic nerve head)

Exclusion Criteria:

- Ocular media opacity in the tumor eye that prevents adequate functional testing or imaging and prior or concurrent retinal or choroidal disease in the tumor eye that prevents adequate functional testing or imaging

Study Design

Related Conditions & MeSH terms

Locations
Country Name City State
United States Jules Stein Eye Institute Los Angeles California

Sponsors (1)
Lead Sponsor Collaborator
Jonsson Comprehensive Cancer Center

Country where clinical trial is conducted

United States, 

See also
  Status Clinical Trial Phase
Active, not recruiting NCT04364230 - Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists In Patients With Melanoma (Including Ocular Melanoma) Phase 1/Phase 2
Completed NCT01200238 - STA-9090(Ganetespib) in Metastatic Ocular Melanoma Phase 2
Completed NCT02858869 - Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases Phase 1
Completed NCT01355120 - THE IPI - Trial in Advanced Melanoma: Melanoma Patients With Advanced Disease Phase 2
Recruiting NCT05524935 - Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma Phase 2
Recruiting NCT05628883 - Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma Phase 1
Active, not recruiting NCT05187884 - Neoadjuvant/Adjuvant Trial of Darovasertib in Ocular Melanoma Phase 2
Recruiting NCT02909517 - The Role of Inflammation in Ocular Tumours
Withdrawn NCT00621439 - Investigative Trial of Interferon Alpha-2b To Shrink Cancer of the Eye N/A
Recruiting NCT03172299 - Prevention of Neovascular Glaucoma by Intravitreal Injections of Anti-VEGF in Patients Treated With Proton Therapy for a Large Choroidal Melanoma Phase 3
Not yet recruiting NCT06432660 - Eye Plaque Brachytherapy for Ocular Melanoma
Completed NCT01893099 - Sorafenib and Radioembolization With Sir-Spheres® for the Treatment of Metastatic Ocular Melanoma Phase 1
Completed NCT00351728 - Combined PET/CT Imaging for the Early Detection of Ocular Melanoma Metastasis Compared to CT Scanning Alone N/A
Active, not recruiting NCT03528408 - Study of Adjuvant Ipilimumab and Nivolumab in Subjects With High-risk Ocular Melanoma Phase 2
Completed NCT03052127 - Study in Subjects With Small Primary Choroidal Melanoma Phase 1/Phase 2
Withdrawn NCT01930968 - Definity for Ultrasound of Intraocular Tumors
Recruiting NCT00168870 - Study of Metastatic Ocular Melanoma Phase 2
Completed NCT02519322 - Neoadjuvant and Adjuvant Checkpoint Blockade Phase 2
Recruiting NCT06007690 - A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma Phase 3
Active, not recruiting NCT04417530 - Phase 2 Trial to Evaluate Belzupacap Sarotalocan (AU-011) Via Suprachoroidal Administration in Subjects With Primary Indeterminate Lesions and Small Choroidal Melanoma Phase 2